Immunotherapy is a new approach for the treatment of lung cancer with impressive long-term results http://bit.ly/35GVzAn
atezolizumab), all showed a clinically and statistically significant advantage over the same standard comparator docetaxel [7-9, 11, 18] . Long-term data were presented and confirmed a long-lasting effect of ICI on overall survival.
Next, those ICI were tested as first line treatment in stage IV NSCLC but showed some conflicting results (table 1) . Monotherapy with pembrolizumab demonstrated significant survival superiority over platinum-based doublets only in a selected group of patients (tumour PDL1 ⩾50%) [11, 12] , while this was not achieved with nivolumab [13] . Conversely, combination of pembrolizumab with chemotherapy had better activity than chemotherapy alone, without excessive supplemental toxicity [14, 15] regardless of the histological subtype or the PDL1 value. Furthermore, atezolizumab showed interesting activity in non-squamous NSCLC, provided bevacizumab was added to the chemotherapy combination [16] , but the activity of this drug remains questionable in squamous histology.
Based on these impressive results, ICI were tested in locoregional NSCLC. The only published phase III trial demonstrated that adjuvant durvalumab in stage III NSCLC non-progressing after concomitant chemo-radiotherapy improved not only progression-free but also overall survival [17] . Also, an early clinical study showed that neo-adjuvant nivolumab before surgical resection led to 40% major pathological response [19] . In this evolving landscape, unpublished phase II and III trials showed promising results [20] with lower major pathological response rates in immunotherapy alone regimens (22% for atezolizumab in LCM3, and 31% for nivolumab with/without ipilimumab in NEOSTAR) than for chemo-immunotherapy regimens (77% for chemotherapy plus nivolumab in NADIM, and 64% for chemotherapy plus atezolizumab). Currently, three large phase III trials are conducted in completely resected stage IB-IIIA NSCLC testing pembrolizumab, nivolumab or durvalumab in an adjuvant strategy. The best sequence for adding immunotherapy to surgery, before or after resection, as well as the integration with chemotherapy needs to be clarified.
As thoracic oncologists did for targeted therapies, clinicians have to learn managing specific toxicities related to the mechanism of action of anti-PD1/PDL1 ICI. Despite some preferential sites being documented, immune-related adverse events may reach any organ at any time, which is different from chemotherapy and targeted therapies. In most of the randomised trials [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , ICI monotherapy is well tolerated (few grade 3-5 adverse events) and discontinuation of treatment for immune-related adverse events is around 5%, while combinations of anti-PD1/PDL1 and anti-CTL4, such as nivolumabipilimumab, are associated with up to 10% grade 3-5 toxicity. Immune-related adverse events such as hypo/hyperthyroidism are observed in up to 10-15% of the patients and might occur as late toxicity; otherwise, the most frequent immune-related adverse events are those affecting the lung, colon, skin and liver, that in some instances could be life-threatening, as well as those considered to be more unusual, such as myocarditis or hypopituitarism. Furthermore, renal failure and interstitial nephritis are potentially problematic in patients receiving ICI-chemotherapy combinations ( platinum-pemetrexed). This implies Nivolumab versus docetaxel 9.2 months versus 6 months <0.001 BORGHAEI et al. [8] Nivolumab versus docetaxel 12.2 months versus 9.4 months 0.002 HERBST et al. [9] Pembrolizumab versus docetaxel 10.4/12.7 months versus 8.5 months <0.001 RITTMEYER et al. [10] Atezolizumab versus docetaxel 13.8 months versus 9.6 months 0.0003 First-line: immunotherapy versus chemotherapy RECK et al. [11] Pembrolizumab versus platinum doublet HR 0.60 (95% CI 0.41-0.89) # 0.005 MOK et al. [12] Pembrolizumab versus platinum doublet 16.7 months versus 12.1 months 0.0018 CARBONE et al. [13] Nivolumab versus platinum doublet 14.4 months versus 13.2 months NS First-line: chemo-immunotherapy versus chemotherapy PAZ-ARES et al. [14] CBDCA-(nab)PTX±pembrolizumab 15.9 months versus 11.3 months <0.001 GANDHI et al. [15] CDDP/CBDCA-PEM±pembrolizumab NR versus 11.3 months <0.001 SOCINSKI et al. [16] CBDCA active detection and management by the thoracic oncologist in conjunction with organ specialists, as well as the conduct of dedicated clinical trials.
These major achievements led to substantial modifications in the therapeutic algorithm for stage III-IV NSCLC and currently, most of those patients are receiving anti-PD1/PDL1 ICI in first or eventually second line and adjuvant after concomitant chemoradiotherapy, as currently reported in the 2019 ESMO guidelines [21] .
However, numerous questions remain, and were approached in the seminar during fruitful discussions (table 2) . Faced with expensive drugs, it is important to define the patients who will most benefit, knowing that up to 30% may present with early progression and/or hyperprogression. Only one validated predictive biomarker is standardised and routinely available, but the accuracy of PDL1 is not sufficient for an individual prediction test in most instances. Other biomarkers, including tumour mutational burden, specific molecular alterations (SKT11, KEAP1) or some immune signatures, are undergoing testing with interesting preliminary results that should be confirmed in prospective studies [29, 30] . A second important question is regarding the management of brain metastases (BM). In almost all randomised trials, patients were only eligible if BM were previously treated and stable. Very limited data [31] suggested that ICI are active on BM, needing further confirmation. Lastly, the best therapeutic algorithm remains to be defined: is an ICI-chemotherapy regimen more active than ICI in the PDL1 ⩾50% subgroup? Is maintenance chemotherapy necessary in those treated with ICI-chemotherapy, or is maintenance ICI sufficient? Which is the role of anti-CTLA4 antibodies? Is combination of ICI (anti-PD1/PDL1 plus anti-CTLA4) an interesting option, may other antigen-delivering agents (vaccination, radiotherapy, targeted drugs, etc.) improve ICI effectiveness? Can ICI be delivered to initially contra-indicated (HIV, Trials <10% Daily practice 27%
• Also ICI benefit for overall survival in elderly patients but increased risk for immune-related adverse events
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Auto-immune disorders [25] 14-25%
• Mainly retrospective data • Higher rate of immune-related adverse events in those with auto-immune disorder compared to those without • Time to immune-related adverse events shorter in those with auto-immune disorder • Survival not different • ICI can be given to patients with auto-immune disorders, especially those without immunosuppressive medication but at increased risk of immune-related adverse events chronic viral infection, auto-immune disease, renal insufficiency) and other specific populations ( poor performance status, elderly, etc.)? What is the optimal duration of immunotherapy and how do we select patients in whom ICI can be stopped without resulting in disease progression? What is the role of rechallenge ICI? How can hyperprogressive patients be identified, and does hyperprogression exist in chemotherapy-ICI treated patients? What are, besides PDL1, biomarkers that can select patients for ICI treatment (or that can identify patients that should not receive ICI at all)? Can patients be re-treated at disease progression when ICI was previously stopped and patients benefited? Is the occurrence of immune-related adverse events a possible prognostic and/or predictive marker of ICI efficacy?
Despite reproducible positive results, only a minority (<20%) of the patients derived a very long-term benefit from ICI immunotherapy and most will progress at any time during treatment. Different strategies are under development and tested in clinical trials, such as new targets, bispecific antibodies, add-in of antigen-delivering drug/technique, combinations with radiotherapy, etc. [32] .
In conclusion, immunotherapy with anti-PD1/PDL1 antibodies profoundly modified our vision in treating locally advanced and metastatic NSCLC and it will probably modify the treatment of earlier disease NSCLC. Currently, immunotherapy alone ( pembrolizumab) or in combination with chemotherapy ( pembrolizumab or atezolizumab) is standard of care for first-line therapy in stage IV NSCLC, while new immunotherapy combinations such as nivolumab-ipilimumab may be another option in a near future. Durvalumab is now the first immunotherapy validated for adjuvant treatment in stage III NSCLC non-progressing after concomitant radiochemotherapy. Many questions remain unresolved and should be clarified in the near future. Those are of importance when considering the financial impact of these drugs if we aim for sustainable, viable health systems.
